{
    "2020-11-25": [
        [
            {
                "time": "2020-11-25",
                "original_text": "复星医药抛近50亿元定增预案 3.25亿用于新冠mRNA疫苗临床及里程碑付款",
                "features": {
                    "keywords": [
                        "复星医药",
                        "定增",
                        "新冠",
                        "mRNA疫苗",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "阿里健康中期调整净利润大增286.4%；先健科技控股子公司元心科技引入战略投资",
                "features": {
                    "keywords": [
                        "阿里健康",
                        "净利润增长",
                        "先健科技",
                        "战略投资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-26",
                "original_text": "A股头条之上市公司（11.26）",
                "features": {
                    "keywords": [
                        "A股",
                        "上市公司"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药(02196)：“18复药02”拟转售金额不超过2.6亿元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "转售",
                        "债券"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药(600196.SH)：BNI拟与LGVW及其全资子公司ClayMergerSub,Inc.进行合并交易",
                "features": {
                    "keywords": [
                        "复星医药",
                        "合并交易",
                        "BNI",
                        "LGVW"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药(02196)拟定增不超过约1.28亿股A股以集资加大对“4+3”研发平台的建设",
                "features": {
                    "keywords": [
                        "复星医药",
                        "定增",
                        "研发平台"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药(600196.SH)：拟就HLX35与Binacea进行开发合作并就该产品向其授予相关许可权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "开发合作",
                        "HLX35",
                        "Binacea"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药在江苏启动新冠疫苗二期临床试验，拟招募960人",
                "features": {
                    "keywords": [
                        "复星医药",
                        "新冠疫苗",
                        "二期临床试验",
                        "招募"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药(02196)和BioNTech(BNTX.US)宣布其新冠候选疫苗BNT162b2将在中国开展二期临床试验",
                "features": {
                    "keywords": [
                        "复星医药",
                        "BioNTech",
                        "新冠疫苗",
                        "BNT162b2",
                        "二期临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-11-25",
                "original_text": "复星医药现1笔大宗交易 共成交538.00万元",
                "features": {
                    "keywords": [
                        "复星医药",
                        "大宗交易"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}